Catalyst

Slingshot members are tracking this event:

FDA accepts IND for Advaxis' (ADXS) drug candidate, ADXS-503, a Phase 1/2 for the treatment of non-small cell lung cancer (NSCLC)

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
ADXS

100%

Additional Information

Additional Relevant Details  Advaxis anticipates that because of this timely allowance, the first patient in the Phase 1/2 trial for this NSCLC drug candidate will be dosed by the end of 2018.
https://ir.advaxis.c...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 30, 2018
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Adxs-503, Phase 1/2, Non-small Cell Lung Cancer